PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Negative revenue growth while GNPX stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
100.00%
Gross profit growth similar to GNPX's 99.98%. Walter Schloss would assume both firms track common industry trends.
-2.59%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-2.59%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-10.34%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-10.26%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-10.26%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.08%
Share reduction more than 1.5x GNPX's 2.91%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.08%
Diluted share reduction more than 1.5x GNPX's 2.95%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
-93.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-94.42%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.91%
Positive long-term OCF/share growth while GNPX is negative. John Neff would see a structural advantage in sustained cash generation.
68.32%
Positive OCF/share growth while GNPX is negative. John Neff might see a comparative advantage in operational cash viability.
41.88%
3Y OCF/share CAGR above 1.5x GNPX's 13.34%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
55.55%
Positive 10Y CAGR while GNPX is negative. John Neff might see a substantial advantage in bottom-line trajectory.
79.95%
Positive 5Y CAGR while GNPX is negative. John Neff might view this as a strong mid-term relative advantage.
56.07%
3Y net income/share CAGR above 1.5x GNPX's 7.33%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
188.20%
10Y equity/share CAGR above 1.5x GNPX's 93.71%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-69.82%
Negative 5Y equity/share growth while GNPX is at 10554.32%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
327.49%
Positive short-term equity growth while GNPX is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-14.02%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-4.69%
We’re deleveraging while GNPX stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
7.04%
R&D dropping or stable vs. GNPX's 60.00%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
-5.63%
We cut SG&A while GNPX invests at 13.17%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.